Loading…
KAPA
Kairos Pharma, LTD.
NYSE American· Healthcare· Biotechnology· CUSIP 48301N104
$0.24-1.62%Price as of Aug 29, 18:46 UTC · updated once a day, after the close
Key metrics
- Market cap
- $5.62M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.28
- ROE
- -113.96%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $2.11
- 52-week low
- $0.22
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -84.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $4.97 | $10.64 | |
| P/B | — | 16.3x | 30.6x |
| EPS | -$0.30 | -$0.23 | |
| ROE | — | -85.90% | -54.50% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| NIKINiki BioSolutions, Inc. | $6.90 | — | 0.3x | — | -17.05% | $5.62M |
| WOKWORK Medical Technology Group LTD | $2.33 | — | 0.0x | — | -19.23% | $5.63M |
| YCBDcbdMD, Inc. | $0.50 | 2.2x | 0.6x | — | -40.33% | $5.6M |
| LIMNLiminatus Pharma, Inc. | $4.23 |
About the company
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
- 1
- Los Angeles, United States
Company description provided by Yahoo Finance.